What class of drugs does dasatinib/staxalide belong to?

Dasatinib (Dasatinib) is a second-generation tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor, TKI), which belongs to a class of targeted anti-cancer drugs. Its core mechanism of action is to efficiently inhibit the kinase activity of BCR-ABL fusion protein, which is a key factor in the occurrence and development of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and certain types of acute lymphoblastic leukemia (Ph+ ALL). The abnormal kinase activity of BCR-ABL can continuously activate downstream signaling pathways, promote unlimited proliferation of leukemia cells and inhibit apoptosis. Dasatinib inhibits the activity of this kinase and disables abnormal signaling pathways, thereby preventing leukemia cell proliferation and inducing apoptosis.

Compared with the first-generation TKI drug imatinib, dasatinib has a broader tyrosine kinase inhibitory spectrum. In addition to inhibiting BCR-ABL, it can also inhibit SRC family kinases and some other related tyrosine kinases, which gives it a clear advantage in patients with imatinib resistance or intolerance. Clinical studies have shown that dasatinib can be used in chronic phase, accelerated phase, myeloid or lymphoblastic phase CML, and is also suitable for Ph+ ALL patients. This broad-spectrum inhibitory ability shows potential value in response to subtypes of drug-resistant mutations such as T315I, providing new options for the treatment of complex cases.

Dasatinib, administered orally, can effectively inhibit the proliferation of cancer cells in the body, and its targeting properties mean that the drug can act more precisely on abnormal kinases while having a relatively limited impact on normal cells, thus improving the safety of treatment to a certain extent. However, the use of dasatinib still requires attention to potential cardiovascular, respiratory, and hematopoietic adverse reactions. It is widely used in clinical practice for patients with drug resistance or relapse, providing a targeted intervention program for the treatment of leukemia.

Reference materials:https://go.drugbank.com/drugs/DB01254